Works matching IS 17582652 AND DT 2022 AND VI 25 AND IP 6
Results: 8
Methodological issues in the designing and reporting of frequentist and Bayesian meta‐analysis to assess COVID‐19 outcomes among PLHIV with various comorbidities.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25946
- By:
- Publication type:
- Article
Turning the tide in HIV through health communication research.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25955
- By:
- Publication type:
- Article
The effect of a Mentor Mothers program on prevention of vertical transmission of HIV outcomes in Zambézia Province, Mozambique: a retrospective interrupted time series analysis.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25952
- By:
- Publication type:
- Article
Improving ART initiation among men who use HIV self‐testing in Malawi: a qualitative study.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25950
- By:
- Publication type:
- Article
Response to "Methodological issues in the designing and reporting of frequentist and Bayesian meta‐analysis to assess COVID‐19 outcomes among PLHIV with various comorbidities" by Ram Bajpai, Vivek Verma and Gyan Prakash Singh.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25947
- By:
- Publication type:
- Article
Women of Worth: the impact of a cash plus intervention to enhance attendance and reduce sexual health risks for young women in Cape Town, South Africa.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25938
- By:
- Publication type:
- Article
HIV testing and linkage to ART following secondary distribution of HIV self‐test kits to male partners of women living with HIV: a pilot randomized control trial in Mpumalanga, South Africa.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25937
- By:
- Publication type:
- Article
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25905
- By:
- Publication type:
- Article